Citi lowered the firm’s price target on AbbVie (ABBV) to $205 from $215 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the firm updated models for its biotechnology and pharmaceuticals coverage. Higher-growth names like Eli Lilly (LLY) and Vertex VRTX) remain Citi’s favorites in the group, given their “strong demand” in key franchises and a lower impact from potential policy changes. The sector “looks tricky” in 2025 given negative sentiment, but growth expectations appear beatable with a focus on commercial execution, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie price target raised to $227 from $220 at Piper Sandler
- Options Volatility and Implied Earnings Moves This Week, January 27 – January 31, 2025
- AbbVie completes acquisition of Nimble Therapeutics
- AbbVie and Neomorph to codevelop molecular glue degraders for onchology
- Johnson & Johnson’s New Acquisition Could Result in Tremendous Rewards